Clinical Trial

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-07-19 -> 2028-01-21 2026-05-06
minor Completion pushed: 2027-07-19 -> 2028-01-21 2026-05-06
Trial Details
NCT Number NCT07235059
Lead Sponsor Novartis Pharmaceuticals
Conditions Chronic Kidney Disease
Enrollment 112 participants
Start Date 2025-11-20
Primary Completion 2028-01-21 (estimated)
Study Completion 2028-01-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-15